AU2009217606B2 - Method for achieving desired glial growth factor 2 plasma levels - Google Patents

Method for achieving desired glial growth factor 2 plasma levels Download PDF

Info

Publication number
AU2009217606B2
AU2009217606B2 AU2009217606A AU2009217606A AU2009217606B2 AU 2009217606 B2 AU2009217606 B2 AU 2009217606B2 AU 2009217606 A AU2009217606 A AU 2009217606A AU 2009217606 A AU2009217606 A AU 2009217606A AU 2009217606 B2 AU2009217606 B2 AU 2009217606B2
Authority
AU
Australia
Prior art keywords
ggf2
myelination
disease
patient
disorder associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009217606A
Other languages
English (en)
Other versions
AU2009217606A1 (en
Inventor
Anthony O. Caggiano
Haesun Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of AU2009217606A1 publication Critical patent/AU2009217606A1/en
Priority to AU2015200220A priority Critical patent/AU2015200220A1/en
Application granted granted Critical
Publication of AU2009217606B2 publication Critical patent/AU2009217606B2/en
Priority to AU2017203961A priority patent/AU2017203961B2/en
Priority to AU2019203654A priority patent/AU2019203654A1/en
Priority to AU2021203369A priority patent/AU2021203369A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2009217606A 2008-02-29 2009-03-02 Method for achieving desired glial growth factor 2 plasma levels Ceased AU2009217606B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2015200220A AU2015200220A1 (en) 2008-02-29 2015-01-19 Method for achieving desired glial growth factor 2 plasma levels
AU2017203961A AU2017203961B2 (en) 2008-02-29 2017-06-13 Method for achieving desired glial growth factor 2 plasma levels
AU2019203654A AU2019203654A1 (en) 2008-02-29 2019-05-24 Method for achieving desired glial growth factor 2 plasma levels
AU2021203369A AU2021203369A1 (en) 2008-02-29 2021-05-25 Method for achieving desired glial growth factor 2 plasma levels

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6758908P 2008-02-29 2008-02-29
US61/067,589 2008-02-29
PCT/US2009/001356 WO2009108390A2 (en) 2008-02-29 2009-03-02 Method for achieving desired glial growth factor 2 plasma levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015200220A Division AU2015200220A1 (en) 2008-02-29 2015-01-19 Method for achieving desired glial growth factor 2 plasma levels

Publications (2)

Publication Number Publication Date
AU2009217606A1 AU2009217606A1 (en) 2009-09-03
AU2009217606B2 true AU2009217606B2 (en) 2015-03-05

Family

ID=41016663

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009217606A Ceased AU2009217606B2 (en) 2008-02-29 2009-03-02 Method for achieving desired glial growth factor 2 plasma levels

Country Status (11)

Country Link
US (5) US8410050B2 (enExample)
EP (3) EP3120863B1 (enExample)
JP (2) JP5697455B2 (enExample)
CN (2) CN102026651B (enExample)
AU (1) AU2009217606B2 (enExample)
BR (1) BRPI0908271A2 (enExample)
CA (1) CA2717193C (enExample)
ES (2) ES2811127T3 (enExample)
PL (2) PL3120863T3 (enExample)
RU (3) RU2530650C2 (enExample)
WO (1) WO2009108390A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026651B (zh) 2008-02-29 2015-06-03 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
CN104707130A (zh) 2008-08-15 2015-06-17 阿索尔达治疗公司 在cns神经性损伤后非-急性期间处理的组合物及方法
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2011147981A2 (en) * 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
WO2012021818A2 (en) * 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
WO2013149163A1 (en) * 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury
WO2018056412A1 (ja) * 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
CN108653274B (zh) * 2017-04-01 2022-09-16 鲁南制药集团股份有限公司 牛蒡子苷元在制备治疗骨髓损伤药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7037888B1 (en) * 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU3003701A (en) * 1999-11-19 2001-05-30 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2005079458A2 (en) * 2004-02-19 2005-09-01 The Regents Of The University Of California ENHANCEMENT OF Th2-DEPENDENT AND INFLAMMATORY RESPONSE
AU2006210537A1 (en) 2005-02-02 2006-08-10 Fox Chase Cencer Center Amine derivative containing compositions and methods for the treatment of viral infections related to the etiology of cancer
CA2658326C (en) 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
US20080003013A1 (en) * 2006-06-30 2008-01-03 Static Control Components, Inc. Cartridge split rail clip
CN102026651B (zh) * 2008-02-29 2015-06-03 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
WO2011123606A1 (en) 2010-04-01 2011-10-06 The Procter & Gamble Company Fabric softener
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns

Also Published As

Publication number Publication date
JP2011513310A (ja) 2011-04-28
US20180055909A1 (en) 2018-03-01
US20130345131A1 (en) 2013-12-26
JP5697455B2 (ja) 2015-04-08
US8410050B2 (en) 2013-04-02
US9272015B2 (en) 2016-03-01
EP3750551A1 (en) 2020-12-16
EP3120863A1 (en) 2017-01-25
PL2262527T3 (pl) 2017-07-31
EP2262527B1 (en) 2016-08-03
ES2613177T3 (es) 2017-05-23
JP5964920B2 (ja) 2016-08-03
EP3120863B1 (en) 2020-05-06
WO2009108390A3 (en) 2010-11-18
US20160367634A1 (en) 2016-12-22
AU2009217606A1 (en) 2009-09-03
CA2717193A1 (en) 2009-09-03
US20210060128A1 (en) 2021-03-04
US10675331B2 (en) 2020-06-09
RU2010139906A (ru) 2012-04-10
RU2687097C2 (ru) 2019-05-07
RU2014131265A (ru) 2016-02-20
ES2811127T3 (es) 2021-03-10
RU2019110452A (ru) 2020-10-09
CN102026651A (zh) 2011-04-20
EP2262527A2 (en) 2010-12-22
RU2530650C2 (ru) 2014-10-10
WO2009108390A2 (en) 2009-09-03
US9744215B2 (en) 2017-08-29
US20100029559A1 (en) 2010-02-04
CN104645315A (zh) 2015-05-27
CN102026651B (zh) 2015-06-03
BRPI0908271A2 (pt) 2017-06-13
CA2717193C (en) 2022-08-16
PL3120863T3 (pl) 2021-02-22
PL2262527T4 (pl) 2017-07-31
JP2015042656A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
US20210060128A1 (en) Method for achieving desired glial growth factor 2 plasma levels
AU2019275508B2 (en) Compositions and methods for treatment during non-acute periods following cns neurological injury
WO2008070132A2 (en) Methods of use of trk receptor modulators
Iaci et al. Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke
AU2017203961B2 (en) Method for achieving desired glial growth factor 2 plasma levels
HK1152230B (en) Compositions for achieving desired glial growth factor 2 plasma levels
Esper Neuregulin, neurotrophic factors, and protein kinase C in axoglial signaling

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired